Appeal No. 2004-1259 Application No. 09/832,355 3. Lack of Written Description and Enablement of fusion proteins with specified half-life The examiner argues there is no written description of fusion proteins with a half- life of at least twice as long as either the first or second peptide portion or both as in claim 6. The examiner argues that “the specification, as filed, does not disclose the half lives of various proteins, nor does it provide any data or working example of the half-life of any of the claimed fusion proteins”, and that the art of increasing half-lives of proteins is unpredictable. Answer, page 11. Appellants respond arguing that (Brief, page 7) methods for determining protein half-life having long been known to those of ordinary skill in the art, and include for example, pulse chase experiments as described in Dandri... and Distelhorst... Moreover the specification discloses specific structural features of the claimed fusion protein, the absence or presence of which enhances protein stability. For example the specification discloses that removal of the Ang-1 coiled-coil domain imparts an increased half-life to a fusion protein comprising Ang-1 as the non-VEGF peptide portion (see, e.g. paragraph [0108], lines 10- 14.) The specification also indicates that the inclusion of cysteine residues in either or both of the VEGF and non-VEGF peptide portions of the claimed fusion protein renders the fusion protein more resistant to extracellular degradation... thereby enhancing protein stability. Fusion protein half-life can also be extended when the non-VEGF peptide portion comprises an IgG domain as described in the specification at paragraph [0108], lines 18-22. The examiner returns, that “it is well known in the art that adding cysteine residues may adversely effect protein folding and activity, and there is no guidance as to where, in any particularly disclosed protein, such cysteine residues could be added.” Answer, page 21. We find no evidence of record cited by the examiner to support this 17Page: Previous 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 NextLast modified: November 3, 2007